06 dec: SimCorps Finanskalender 2017
06 dec: Finanskalender 2017
06-12-2016 15:16:09

Chr. Hansen Holding A/S appoints new Chief Scientific Officer

Relateret indhold
16 feb - 
Nestlés vækst skuffer ledelsen og aktiemarkedet
15 feb - 
Aktier/tendens: Stigninger i vente - finansaktier og Ge..
15 feb - 
Chr. Hansen-rival sparer sig til højere indtjening
Relateret debat
20 feb - 
Mange mange tak
20 feb - 
PURE, HBIO, ROKA, PLSE, PACB
20 feb - 
Hvilke andre firmaer arbejder med samme forretningsomr&..

Hoersholm, 2016-12-06 15:16 CET (GLOBE NEWSWIRE) --

 

Company announcement No. 25/2016

Chr. Hansen Holding A/S has entered into an agreement with Thomas Schäfer to take up the position of Executive Vice President and Chief Scientific Officer.

Thomas is currently employed as Vice President at Novozymes and will take up his new position as soon as possible, which is expected to be during spring 2017.

A German national, Thomas completed his Ph.D. in Microbiology, Physiology & Biochemistry and worked as an assistant professor at Freie Universität Berlin. He started his commercial career as a post doc and has since 1994 held various senior leadership positions in the R&D space at Novozymes.

Thomas has more than 20 years’ experience in industrial microbiology, R&D, Innovation, business development and M&A, covering both bacteria and enzymes. He has published several papers, and is the co-founder of a number of patents.

Cees de Jong, CEO of Chr. Hansen, says: “I’m pleased to welcome Thomas to Chr. Hansen as we continue to strengthen our capabilities within the microbial platform and our leadership position in bacterial fermentation technology.”

Following this appointment, the Executive Board will consist of: CEO Cees de Jong, CFO Søren Westh Lonning, COO Knud Vindfeldt, and CSO Thomas Schäfer.

 

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel: +45 4574 7618

Camilla Lercke, Head of Media Relations

Tel: +45 5339 2384

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen A/S. For further information, please visit www.chr-hansen.com.

Vedhæftet fil: No 25 2016 US.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/middag: Mærsk og Genmab i C20-bunden og dukkert til Rockwool

24-02-2017 11:44:51
Trods yderligere fremgang til ISS, der torsdag leverede et stærkt regnskab, ligger det danske aktiemarked fredag middag i et minus efter fald i aktier som Mærsk..

Aktier/tendens: Rockwool-tal og analytikerændringer sætter retningen

24-02-2017 08:32:38
Der er udsigt til en rolig start på fredagens danske aktiehandel, hvor regnskaber fra en stribe mellemstore selskaber vil tage opmærksomhed og være med til at s..

Genmab-boss' aktiepost krydser 1,5 mia. kr. efter rekordregnskab

23-02-2017 16:10:14
Genmab har de seneste år været en gylden investering for selskabets aktionærer, men ingen enkeltpersoner har formentlig tjent så mange penge på aktiekursens him..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab-boss' aktiepost krydser 1,5 mia. kr. efter rekordregnskab
2
Genmab/SEB: Giver en af de få forsigtige anbefalinger
3
Vestas-rival viser stor fremgang over hele linjen
4
Aktier/tendens: Rockwool-tal og analytikerændringer sætter retningen
5
Torsdagens aktier: Fald til C20 trods plusser til WDH og Genmab

Relaterede aktiekurser

Chr Hansen Holding A/S 415,40 -0,4% Fald i aktiekurs
CHR Hansen Hldg DKK10 59,64 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. februar 2017 13:47:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB2 - 2017-02-24 13:47:44 - 2017-02-24 13:47:44 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x